Ipragliflozin is indicated in the?treatment of type 2 diabetes. Ipragliflozin was developed by Astellas Pharma Inc. Kotobuki Pharmaceutical Co. Ltd..
The API has now reached off-patent status, after being launched in 2014.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Ipragliflozin and many others, contact info@pharmacheminvestor.com